Key result
This review provides an overview of currently approved and investigational drug-eluting stents, focusing on new anti-restenotic agents, polymeric coatings, and stent platforms.
This review provides an overview of the evolution and current state of drug-eluting stents for coronary artery disease, highlighting efforts to improve long-term safety and efficacy.
Offers clinicians a current DES overview; leaves open which platforms best balance long-term safety and efficacy.
Over the past decade the introduction of drug-eluting stents (DESs) has revolutionised the treatment of coronary artery disease. However, in recent years concern has arisen over the long-term safety and efficacy of DESs due to the occurrence of late adverse clinical events such as stent thrombosis. With this concern in mind, research and development is currently centred on increasing the long-term safety and efficacy of DESs. The aim of this paper is to provide a thorough review of currently approved and promising investigational DESs. With dozens of companies involved in the development of new and innovative anti-restenotic agents, polymeric coatings and stent platforms, it is intended that this review paper will provide a clear indication of how DESs are currently evolving and prove a valuable reference tool for future research in this area.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2010) conducted a review in Coronary artery disease. Drug-eluting stents was evaluated. This review provides an overview of currently approved and investigational drug-eluting stents, focusing on new anti-restenotic agents, polymeric coatings, and stent platforms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: